20

Shares

News site default image

FDA grants accelerated approval to new treatment for advanced soft tissue sarcoma

Shared by Radhika Narayanan | 0 19 1 | about 9 months ago

FDA News Release October 19, 2016 The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment.

Read More On www.fda.gov

Categories FDA Wellness & Prevention

Related Post

Links

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm
http://www.fda.stfi.re/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm?sf=gpgyjjb
http://stfi.re/gpgyjjb
http://bit.ly/2ejPB1h

0 Votes

You must log in to post a comment

0 Comments